Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Closed Good Friday 04-17 16:00:00 EDT

234.56

+4.06

+1.76%

盘后234.56

+0.000.00%

18:18 EDT

High235.12	Low228.96	Vol601.35K
Open230.48	D1 Closing230.50	Amplitude2.67%
Mkt Cap30.37B	Tradable Cap29.19B	Total Shares129.46M
T/O140.34M	T/O Rate0.48%	Tradable Shares124.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":234.56,"timestamp":1744920000000,"preClose":230.5,"halted":0,"volume":601350,"hourTrading":{"tag":"盘后","latestPrice":234.56,"preClose":234.56,"latestTime":"18:18 EDT","volume":28563,"amount":6699748.61,"timestamp":1744928295505},"delay":0,"floatShares":124460614,"shares":129457156,"eps":-2.179042,"marketStatus":"Closed Good Friday","change":4.06,"latestTime":"04-17 16:00:00 EDT","open":230.48,"high":235.12,"low":228.96,"amount":140336845.041,"amplitude":0.026725,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.179042,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":230.5,"preHourTrading":{"tag":"盘前","latestPrice":232,"preClose":230.5,"latestTime":"09:17 EDT","volume":436,"amount":100783.07424,"timestamp":1744895835520},"postHourTrading":{"tag":"盘后","latestPrice":234.56,"preClose":234.56,"latestTime":"18:18 EDT","volume":28563,"amount":6699748.61,"timestamp":1744928295505},"volumeRatio":0.48495818270051816,"impliedVol":0.5324,"impliedVolPercentile":0.7849},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"2528742110","title":"BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2528742110","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528742110?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 23:09","pubTimestamp":1744902557,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) has an average rating of overweight and mean price target of $318.89, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY"],"gpt_icon":0},{"id":"2528716251","title":"Press Release: Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2528716251","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528716251?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 20:03","pubTimestamp":1744891380,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4604","BK4022","BK4585","BK4099","BK4139","03160","BK4232","BK4555","BK4548","TM","ALNY","BK4588"],"gpt_icon":0},{"id":"2527446114","title":"Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527446114","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527446114?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 02:03","pubTimestamp":1744653783,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.  stands against other best growth stocks to buy according to billionaires.Can the Stock Market Have a Big Rebound?Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-inc-alny-best-180303257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","NVIW.SI","QID","SQQQ","TSYW.SI","USJW.SI","MNQmain","PSQ","ALNY","BK4585","NQmain",".IXIC","BK4139","BK4588","QLD","TQQQ","BK4548"],"gpt_icon":1},{"id":"2527984111","title":"High Growth Tech Stocks In US With Potential For Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2527984111","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527984111?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 01:38","pubTimestamp":1744652290,"startTime":"0","endTime":"0","summary":"The United States market is currently experiencing a mixed performance with major indexes such as the Dow Jones and S&P 500 showing modest gains, while the tech-heavy Nasdaq Composite has seen slight declines amid fluctuating trade policies and tariff exemptions. In this dynamic environment, identifying high growth tech stocks with potential for expansion requires careful consideration of factors such as innovation, market adaptability, and resilience to external economic pressures.Top 10 High Growth Tech Companies In The United States. Overview: Ascendis Pharma A/S is a biopharmaceutical company specializing in the development of TransCon-based therapies for unmet medical needs across Denmark, Europe, North America, and globally, with a market cap of approximately $9.04 billion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-us-173810721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASND","BK4548","BK4588","NTRA","ALNY","BK4139","BK4585"],"gpt_icon":0},{"id":"2526052630","title":"How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2526052630","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526052630?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 17:30","pubTimestamp":1744363800,"startTime":"0","endTime":"0","summary":"The U.S. biotech sector had already been through a brutal few years before the latest market crash. Robert F. Kennedy Jr. shake-up of the nation's health agencies and persistently high interest rates are prompting it to sink even faster than the broader market, despite so far avoiding the worst of the tariff fallout.More investors are even wondering if the whole model -- risky science, costly funding, political uncertainty and long waits for payoffs -- is simply broken. For many of the nearly 200 companies trading below their cash value, it probably is. That illustrates the pitfalls of passively investing in an index for this sector.Despite that bleak backdrop, there are still some opportunities for patient investors. After all, the U.S. is still the top spender on drugs by far. And that isn't something RFK Jr. or President Trump is likely to change.\"We lost our leadership in semiconductors, and we are close to losing that position in biotech if we don'","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","BBIO","LU0471298694.HKD","LU0882574139.USD","LU1035775433.USD","LU1267930730.SGD","LU0289739699.SGD","ALNY","LU2471134523.USD","VRTX","LU2462157665.USD","LU0203201768.USD","CGON","LU0256863902.USD","LU2237443978.SGD","XBI","GILD","LU0823416689.USD","BK4505","LU0354030511.USD","LU1551013425.SGD","LU2362541273.HKD","LU1814569148.SGD","LU2750360641.GBP","LU0198837287.USD","LU2237443549.SGD","IE00B3T34201.USD","LU2491050154.USD","GB00BDT5M118.USD","LU0640476718.USD","LU2360106947.USD","LU1069344957.HKD","SG9999014906.USD","SG9999018865.SGD","IE0002270589.USD","IE00BZ9MQY76.HKD","CYTK","SG9999017495.SGD","LU0889565916.HKD","LU0061475181.USD","SGXZ57979304.SGD","IE00BJLML261.HKD","LU1868836914.USD","LU0106261372.USD","LU2324357040.USD","SG9999015945.SGD","LU2552382058.USD","LU1712237335.SGD","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2526594577","title":"Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526594577","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526594577?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 21:32","pubTimestamp":1744291920,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  shares rallied 8.5% in the last trading session to close at $243.27. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6% loss over the past four weeks.The rise in share price came after President Trump announced a 90-day pause on his sweeping tariffs against non-retaliating countries.For Alnylam, the consensus EPS estimate for the quarter has been revised 1.5% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on ALNY going forward to see if this recent jump can turn into more strength down the road.Alnylam is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Immunome, Inc. , finished the last trading session 11.7% higher at $6.21. IMNM has returned -36.3% over the past month.This a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-alny-moves-8-5-133200351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4563","BK4588","ALNY","IMNM","BK4548","BK4585"],"gpt_icon":0},{"id":"2526007363","title":"Alnylam Pharmaceuticals Price Target Maintained With a $320.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2526007363","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526007363?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:18","pubTimestamp":1744201080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 08:18 ET (12:18 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2526841924","title":"Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526841924","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526841924?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 02:08","pubTimestamp":1744135737,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.  stands against other best long term growth stocks to buy according to billionaires.As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, immigration, and global geopolitics, resulting in elevated levels of uncertainty and volatility, with markets witnessing a range of policy changes. The firm’s research analysts opine that higher uncertainty comes at a cost to global growth. In the US, there has been a decline in consumer confidence, while personal spending remains weak, and GDP forecasts declined sharply, says the firm.To list the 10 Best Long Term Growth Stocks to Buy According to Billionaires, we used a screener and Insider Monkey’s exclusive database of billionaire stock holdings to shortlist the companies that have exhibited at least ~20% ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-inc-alny-best-180857344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PSQ","USAW.SI","ALNY","TQQQ","BK4548","BK4588","QID","SQQQ","QLD","USJW.SI","NVIW.SI","NQmain","BK4585","MNQmain","TSYW.SI",".IXIC"],"gpt_icon":1},{"id":"2525768178","title":"Alnylam Pharma (ALNY) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2525768178","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525768178?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 09:48","pubTimestamp":1743817710,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on April 3 and set a price target of $330.00. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-receives-a-buy-from-rbc-capital-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-receives-a-buy-from-rbc-capital-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4207","ALNY","BK4139","BK4548"],"gpt_icon":0},{"id":"2525564207","title":"Top Analyst Reports for Broadcom, UnitedHealth & Toyota Motor","url":"https://stock-news.laohu8.com/highlight/detail?id=2525564207","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525564207?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 04:54","pubTimestamp":1743800040,"startTime":"0","endTime":"0","summary":"Friday, April 4, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-analyst-reports-broadcom-unitedhealth-205400491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2236285917.USD","LU0353189763.USD","UNH","BK4532","IE0034235188.USD","LU1854104046.USD","BK4515","LU0081259029.USD","AVGOP","HRL","AVGO","MHK","BK4533","LW","TM","LU0097036916.USD","LU0162691827.USD","LU0211326755.USD","LU1935042991.SGD","CEG","VEEV","LU2272731782.SGD","LU0106259046.USD","LU1093756168.USD","IE0009354923.USD","LU2471134879.HKD","IE0002270589.USD","LU0672654240.SGD","AMX","LU1267930490.SGD","LU0957808578.USD","BK4006","GRMN","PPIH","SNDR","LU1551013425.SGD","LU1718418525.SGD","NOG","03160","BK4213","CSTA.U","ALNY","LU2602419157.SGD","IE00B7SZLL34.SGD","LU2347655156.SGD","SGXZ57979304.SGD","CRS","LPLA","LU0029864427.USD","HII"],"gpt_icon":1},{"id":"2524208016","title":"Canaccord Genuity Remains a Buy on Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524208016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524208016?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:15","pubTimestamp":1743765349,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Whitney Ijem from Canaccord Genuity reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a pric...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ALNY","BK4139","BK4585","BK4548"],"gpt_icon":0},{"id":"2524928416","title":"Alnylam Pharmaceuticals Price Target Maintained With a $500.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524928416","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524928416?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 00:19","pubTimestamp":1743610740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 12:19 ET (16:19 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2524145956","title":"SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2524145956","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524145956?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 21:44","pubTimestamp":1743515040,"startTime":"0","endTime":"0","summary":"SanofiSNY and partner,Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia  as the first antithrombin-lowering  therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients  with hemophilia A or B with or without factor VIII or IX inhibitors in the United States.Hemophilia A and B are rare, lifelong congenital bleeding disorders that impair the blood's ability to clot, causing excessive bleeding and spontaneous joint bleeds. These can lead to joint damage, chronic pain, which takes a significant toll on the patients’ quality of life.This FDA approval is based on positive data from the phase III ATLAS studies of Qfitlia, which showed clinically significant bleed protection, as measured by annualized bleeding rates , in hemophilia patients with or without inhibitors.Year to date, SNY stock has gained 15% compared with the industry’s 3.4% growth.Further analysis in the open-label extension study, under the ATL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sny-gets-fda-nod-first-134400996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","SNY","BK4532","BK4588","LU1559883803.SGD","ABR","BK4139","ALNY","BK4007","CORT","LU0566484027.USD","BAYRY","BK4548","IE00BFXG1179.USD","BK4211","BK4585","UBCP"],"gpt_icon":0},{"id":"2524156101","title":"Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524156101","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524156101?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:00","pubTimestamp":1743508800,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 01, 2025----Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-webcast-presentation-needham-24th-120000909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","ALNY","BK4548","BK4588","HCSG","BK4137"],"gpt_icon":0},{"id":"2524047975","title":"BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=2524047975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524047975?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 02:29","pubTimestamp":1743445744,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, AppleMarch 31 (Reuters) - The S&P 500 and the Nasdaq declined on Monday, with technology stocks among the largest fallers, as inves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3N3QE16T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673691.USD","NVAX","EBS","LU1145028129.USD","BK4539","GSK.UK","IIPR","NEM","GLPI","HMST","SSBK","LPLA","PG","LU1674673428.USD","FLG","SRPT","BK4532","COOP","LITB","GATE","LU0316494557.USD","LYV","LU0061475181.USD","ALSN","PL","GT","RKT","ENZ","SLDB","BK4017","SG9999015358.SGD","TSYW.SI","LU0820561818.USD","NOVA","AIG","LU2552382215.SGD","TSHA","VBTX","PINS","FBK","SG9999014567.USD","ELTX","BLUE","IDYA","ALNY"],"gpt_icon":1},{"id":"2523400699","title":"BUZZ-Stifel expects Alnylam's heart disease drug to be 'go-to therapy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2523400699","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523400699?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 22:06","pubTimestamp":1743429987,"startTime":"0","endTime":"0","summary":"BUZZ-Stifel expects Alnylam's heart disease drug to be 'go-to therapy'** Brokerage Stifel raises PT on drugmaker Alnylam Pharmaceuticals' ALNY.O to $345 from $300 following expanded U.S. approval for its heart disease drug** The new PT represents a 28.5% upside to the stock's last close ** Brokerage believes ALNY's drug Amvuttra will be a \"go-to therapy\" for patients with heart disease condition who progress on a stabilizer** Amvuttra, a quarterly injection, was cleared to treat ATTR-CM, a condition where faulty transthyretin proteins accumulate in the heart and potentially causing organ to fail** Stifel says physician feedback on the drug has been broadly favorable** Twenty four of 31 brokerages rate the stock \"buy\" or higher, 7 \"hold\"; their median PT is $316.71, according to data compiled by LSEG** As of last close, ALNY has risen 80% in past 12 months  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL6N3QE0HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4548","ALNY","BK4139","BK4585"],"gpt_icon":0},{"id":"2523094122","title":"Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094122","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094122?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:59","pubTimestamp":1743425996,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  said late Friday that the US Food and Drug Administration approved Qfitlia, a therapy designed to lower antithrombin, a protein inhibiting blood clotting.The company said Qfitlia is approved for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients with hemophilia A or B.Regulatory submissions have also been completed for Qfitlia in China and Brazil, it added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY","BK4588","BK4585","BK4139","BK4548"],"gpt_icon":0},{"id":"2523949132","title":"FDA Approves Sanofi's Hemophilia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949132","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949132?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:28","pubTimestamp":1743424092,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration on Friday approved Sanofi SA’s  Qfitlia , the first antithrombin-lowering  therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients  with hemophilia A or B with or without factor VIII or IX inhibitors.The approval is based on data from the ATLAS phase 3 studies that demonstrated clinically meaningful bleed protection as measured by annualized bleeding rates .Also Read: Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal. By lowering AT, a protein that inhibits blood clotting, Qfitlia helps increase thrombin generation to restore hemostasis in hemophilia patients.In the ATLAS clinical development program, Qfitlia demonstrated low bleed rates across subgroups with as few as six injections a year. Key results include:. Significant bleed reduction by 71% in ABR for patients without inhibitors treated with Qfitlia prophylaxis compared to clotting factor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-sanofis-hemophilia-drug-122812095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNYNF","BK4548","SNY","ALNY","BK4007","BK4585","BK4588","BK4110","ABR","IE00BFXG1179.USD","BK4139"],"gpt_icon":0},{"id":"2523943467","title":"Alnylam Pharmaceuticals Is Maintained at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2523943467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523943467?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:55","pubTimestamp":1743422100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 07:55 ET (11:55 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","ALNY"],"gpt_icon":0},{"id":"2523917133","title":"Scotiabank Remains a Buy on Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917133?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:05","pubTimestamp":1743419140,"startTime":"0","endTime":"0","summary":"In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/scotiabank-remains-a-buy-on-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/scotiabank-remains-a-buy-on-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4548","ALNY","BK4588","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0366},{"period":"1month","weight":-0.0399},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.2074},{"period":"1year","weight":0.6141},{"period":"ytd","weight":-0.0032}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.037108},{"month":2,"riseRate":0.47619,"avgChangeRate":0.003609},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.013154},{"month":4,"riseRate":0.380952,"avgChangeRate":-0.02476},{"month":5,"riseRate":0.6,"avgChangeRate":0.035453},{"month":6,"riseRate":0.619048,"avgChangeRate":0.064199},{"month":7,"riseRate":0.666667,"avgChangeRate":0.102356},{"month":8,"riseRate":0.571429,"avgChangeRate":0.032179},{"month":9,"riseRate":0.52381,"avgChangeRate":0.035035},{"month":10,"riseRate":0.380952,"avgChangeRate":-0.044018},{"month":11,"riseRate":0.761905,"avgChangeRate":0.082821},{"month":12,"riseRate":0.47619,"avgChangeRate":0.012209}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction